[CuZn-SOD determination of sera in patients with rheumatic diseases].
Superoxide anion (O2.-) plays an important part in reactive oxygen species (ROS). In order to explore its effect on the pathogenesis of rheumatic diseases, authors had determined CuZn-SOD contents of sera in 132 subjects involving the patients of rheumatic diseases (SLE, RA, etc), non-rheumatic diseases and normal controls by using enzyme linked immunosorbent assay (ELISA). The results showed the followings: CuZn-SOD contents of 27 normal subjects: 98.80 +/- 20.74 ng/ml (x +/- s); that of 27 non-rheumatic diseases cases: 72.24 +/- 16.60 ng/ml (x +/- s); of 22 SLE cases: 56.56 +/- 19.27 ng/ml (x +/- s); of 27 RA cases: 61.56 +/- 20.53 ng/ml (x +/- s); of 29 other rheumatic diseases cases: 68.97 +/- 17.79 ng/ml (x +/- s). Statistical test was made: both CuZn-SOD contents of rheumatic disease and non-rheumatic disease were lower than that of normal subjects with more significant difference (P < 0.001); compared with that of non-rheumatic diseases patients, SLE cases had significant difference (P < 0.01); RA cases had significant difference (P < 0.05); other cases of rheumatic diseases had no statistical differrence (P > 0.05). Above results suggest that superoxide anion is a non-specific inflammatory mediator which contributes to disorders with inflammatory damages (rheumatic or non-rheumatic diseases), where CuZn-SOD content tested was obviously lower than normal subjects; among the rheumatic disease patients, CuZn-SOD contents of the sera of SLE patients were the lowest because of its more autoimmune antibody, more severe inflammatory and immunological reaction. This work laid the theoretical and experimental foundation for the clinical application of exogenous CuZn-SOD in the treatment of rheumatic diseases. Combined use of CuZn-SOD scavengers may get better result because of the complexibility of ROS inflammatory mechanism.